Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 8Neoplasms 4Prostate Cancer Metastatic 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Solid Cancer 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Malignant Solid Tumor - Malignant Nervous System Neoplasm 1Lymphadenopathy 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Gemcitabine 79Cisplatin 56pembrolizumab 32Paclitaxel 28Carboplatin 24Docetaxel 19Radiotherapy 17Mitomycin 16Doxorubicin 15atezolizumab 14BCG Vaccine 14Nivolumab 13Cystectomy 13Filgrastim 11vinflunine 10Methotrexate 10Vinblastine 9Fluorouracil 95-aminolevulinic acid hexyl ester 9Sunitinib 7Early Intervention, Educational 7durvalumab 6avelumab 6Taxes 6Methods 6Cystoscopy 6Albumin-Bound Paclitaxel 6enfortumab vedotin 5Trastuzumab 5Surveys and Questionnaires 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urinary Bladder Neoplasms × XRP6258 × Clear all
NCT01668459 2018-12-04

CabB1

University Hospital Birmingham NHS Foundation Trust

Phase 2/3 Completed
20 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡